Glycemic control with Glyburide/Metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial (original) (raw)

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

mark jonh

… England Journal of …, 2006

View PDFchevron_right

Addition of Rosiglitazone to Glimepirid and Metformin Combination Therapy in Type 2 Diabetes

Mehmet Sargin

Endocrine Journal, 2004

View PDFchevron_right

Triple Therapy in Type 2 Diabetes: Insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients

Poul Strange

Diabetes Care, 2006

View PDFchevron_right

Twice-daily dosing of a repaglinide/metformin fixed-dose combination tablet provides glycaemic control comparable to rosiglitazone/metformin tablet

Philip Raskin

Diabetes, Obesity and Metabolism, 2009

View PDFchevron_right

Rosiglitazone in Combination With Glimepiride Plus Metformin in Type 2 Diabetic Patients

Gennie Vlachou

Diabetes Care, 2002

View PDFchevron_right

Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes

Juan Barbosa

Diabetes-metabolism Research and Reviews, 2002

View PDFchevron_right

Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial

Arrigo Cicero

Diabetes, Obesity and Metabolism, 2006

View PDFchevron_right

A comparison of preconstituted, fixed combinations of low-dose glyburide plus metformin versus high-dose glyburide alone in the treatment of type 2 diabetic patients

Alessandro Coppini

Acta Diabetologica, 1999

View PDFchevron_right

Effects of Rosiglitazone, Glyburide, and Metformin on -Cell Function and Insulin Sensitivity in ADOPT

B. Zinman

Diabetes, 2011

View PDFchevron_right

A Comparison of the Effects of Rosiglitazone and Glyburide on Cardiovascular Function and Glycemic Control in Patients With Type 2 Diabetes

Paresh Dandona

Diabetes Care, 2002

View PDFchevron_right

Comparison of metformin, gliclazide MR and rosiglitazone in monotherapy and in combination for type 2 diabetes

Lucio Vilar

Arquivos Brasileiros de Endocrinologia & Metabologia, 2010

View PDFchevron_right

Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes

Luc Van Gaal

Diabetes, Obesity and Metabolism, 2003

View PDFchevron_right

An open level study to assess the glycemic control effect of metformin and Pioglitazone as add on therapy along with sulfonylurea in uncomplicated type2 …

goutameswar mazumdar

Journal of Diabetes Mellitus, 2012

View PDFchevron_right

Renal Function in Type 2 Diabetes with Rosiglitazone, Metformin, and Glyburide Monotherapy

Barbara Kravitz

Clinical Journal of the American Society of Nephrology, 2011

View PDFchevron_right

Metabolic effects of rosiglitazone and metformin in Greek patients with recently diagnosed type 2 diabetes

Dimitrios Karamitsos

In vivo (Athens, Greece)

View PDFchevron_right

An open level study to assess the glycemic control effect of metformin and Pioglitazone as add on therapy along with sulfonylurea in uncomplicated type2 diabetes mellitus

Anindya Dasgupta

Journal of Diabetes Mellitus, 2012

View PDFchevron_right

Glycemic Control in Type 2 Diabetes (Drug Treatments)

Floris Laar

View PDFchevron_right

COMPARATIVE STUDY TO EVALUATE EFFICACY AND SAFETY OF PIOGLITAZONE VERSUS VOGLIBOSE ON GLYCEMIC PARAMETERS IN PREDIABETES PATIENTS ADD ON METFORMIN

Dr Mohd F A H E E M Mubeen

View PDFchevron_right

Induction of long-term glycemic control in type 2 diabetic patients using pioglitazone and metformin combination

Vijay Panikar

The Journal of the Association of Physicians of India, 2007

View PDFchevron_right

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

Byron Hoogwerf

The Lancet, 2006

View PDFchevron_right

Addition of biphasic insulin aspart 30 to rosiglitazone in type 2 diabetes mellitus that is poorly controlled with glibenclamide monotherapy

Julius Vaz

Clinical Therapeutics, 2003

View PDFchevron_right

Glycemic control in patients with type 2 diabetes mellitus switched from twice-daily immediate-release metformin to a once-daily extended-release formulation

Frank Lauster

Clinical Therapeutics, 2003

View PDFchevron_right

Rosiglitazone Therapy Improves Insulin Resistance Parameters in Overweight and Obese Diabetic Patients Intolerant To Metformin

Arrigo Cicero

Archives of Medical Research, 2008

View PDFchevron_right

Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with Type II diabetes

Philip Raskin

Diabetologia, 2000

View PDFchevron_right

Efficacy of Some Combination Regimens of Oral Hypoglycaemic Agents in Type 2 Diabetes Mellitus Patients

Endang Kumolosasi

Tropical Journal of Pharmaceutical Research, 2015

View PDFchevron_right

Effect of Glyburide—Metformin Combination Tablet in Patients with Type 2 Diabetes

Nain-Feng Chu

Journal of the Chinese Medical Association, 2007

View PDFchevron_right

Improved glycaemic control with metformin–glibenclamide combined tablet therapy (Glucovance®) in Type 2 diabetic patients inadequately controlled on metformin

Lehert Philippe

Diabetic Medicine, 2002

View PDFchevron_right

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

Arnaud Bastien

The Lancet, 2010

View PDFchevron_right